D
David J. Graham
Researcher at Center for Drug Evaluation and Research
Publications - 111
Citations - 7053
David J. Graham is an academic researcher from Center for Drug Evaluation and Research. The author has contributed to research in topics: Population & Warfarin. The author has an hindex of 34, co-authored 105 publications receiving 6493 citations. Previous affiliations of David J. Graham include Food and Drug Administration & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
David J. Graham,David Campen,Rita Hui,Michele M. Spence,Craig Cheetham,Gerald Levy,Stanford Shoor,Wayne A. Ray,Wayne A. Ray +8 more
TL;DR: Rofecoxib use increases the risk of serious coronary heart disease compared with celecoxib use, and naproxen use does not protect against serious coronaryHeart disease.
Journal ArticleDOI
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
David J. Graham,Judy A. Staffa,Deborah Shatin,Susan E. Andrade,Stephanie D. Schech,Lois La Grenade,Jerry H. Gurwitz,K. Arnold Chan,Michael J. Goodman,Richard Platt +9 more
TL;DR: Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastsatin, and simvastsatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus.
Journal ArticleDOI
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
David J. Graham,Marsha E. Reichman,Michael Wernecke,Rongmei Zhang,Mary Ross Southworth,Mark Levenson,Ting-Chang Sheu,Katrina Mott,Margie R. Goulding,Monika Houstoun,Thomas E. MaCurdy,Chris Worrall,Jeffrey A. Kelman +12 more
TL;DR: In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with nonvalvular atrial fibrillation.
Journal ArticleDOI
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham,Rita Ouellet-Hellstrom,Thomas E. MaCurdy,Farzana Ali,Christopher Sholley,Christopher M. Worrall,Jeffrey A. Kelman +6 more
TL;DR: Compared with prescription of pioglitazone, prescription of rosig litazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increase risk of the composite of AMI, stroke,heart failure, or all- cause mortality in patients 65 years or older.
Journal ArticleDOI
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
David J. Graham,Marsha E. Reichman,Michael Wernecke,Ya-Hui Hsueh,Rima Izem,Mary Ross Southworth,Yuqin Wei,Jiemin Liao,Margie R. Goulding,Katrina Mott,Yoganand Chillarige,Thomas E. MaCurdy,Chris Worrall,Jeffrey A. Kelman +13 more
TL;DR: Treatment with rivaroxaban 20 mg once daily was associated with statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily, which indicated increased risk of stroke, bleeding, and mortality in patients with nonvalvular atrial fibrillation.